51. 全身性強皮症 Scleroderma Clinical trials / Disease details

臨床試験数 : 525 / 薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217

3 trials found

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05149768 (ClinicalTrials.gov)	September 1, 2023	24/11/2021	Open Label Extension Study of Brentuximab Vedotin in Early dcSSc	An Open Label Extension Study of Brentuximab VedotinTreatment in Active Diffuse Cutaneous Systemic S ...	Diffuse Cutaneous Systemic Sclerosis	Drug: Brentuximab vedotin	Lawson Health Research Institute	Seagen Inc.	Not yet recruiting	18 Years	N/A	All	10	Phase 2	NULL
2	NCT03198689 (ClinicalTrials.gov)	May 7, 2019	14/6/2017	Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis	A Pilot Study of Adcetris Treatment in Active Diffuse Cutaneous Systemic Sclerosis (Diffuse Sclerode ...	Diffuse Cutaneous Systemic Sclerosis	Drug: Brentuximab Vedotin	Lawson Health Research Institute	Seagen Inc.	Active, not recruiting	18 Years	N/A	All	11	Phase 2	Canada
3	NCT03222492 (ClinicalTrials.gov)	September 20, 2017	17/7/2017	Brentuximab Vedotin for Systemic Sclerosis	Evaluation of Brentuximab Vedotinfor Diffuse Cutaneous Systemic Sclerosis BRAVOS: A Phase 1/2 Multic ...	Diffuse Cutaneous Systemic Sclerosis;Scleroderma;dcSSc	Biological: Brentuximab Vedotin;Biological: Placebo	National Institute of Allergy and Infectious Diseases (NIAID)	Immune Tolerance Network (ITN);Seagen Inc.;PPD;Rho Federal Systems Division, Inc.	Active, not recruiting	18 Years	70 Years	All	17	Phase 1/Phase 2	United States;Canada

First Previous1Next Last